Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2985

1.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

2.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

3.

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.

Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J.

Health Technol Assess. 2008 May;12(21):iii, xi-xiii, 1-212. Review.

4.

Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.

Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. Review.

6.

Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.

Vrecer M, Turk S, Drinovec J, Mrhar A.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):567-77.

PMID:
14692706
7.
8.

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS.

Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. Review.

9.

Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.

Ara R, Pandor A, Stevens J, Rees A, Rafia R.

Health Technol Assess. 2009 Jul;13(34):1-74, 75-118. doi: 10.3310/hta13340. Review.

10.

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.

PMID:
16520473
11.
12.

Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.

Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A.

Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. Review.

13.

Lipid-lowering drug therapy in elderly patients.

Berthold HK, Gouni-Berthold I.

Curr Pharm Des. 2011;17(9):877-93. Review.

PMID:
21418034
14.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.

16.

Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.

Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L.

Curr Med Res Opin. 2008 Jun;24(6):1823-32. doi: 10.1185/03007990802144705. Epub 2008 May 15.

PMID:
18485270
17.

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.

PMID:
10819699
18.

Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.

Lim SS, Vos T, Peeters A, Liew D, McNeil JJ.

Med J Aust. 2001 Nov 5;175(9):459-64.

PMID:
11758073
19.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

20.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388

Supplemental Content

Support Center